Jacob Elgrably - Rekah Pharmaceutical Chief Shalpharm
| REKA Stock | ILA 1,400 8.00 0.57% |
Insider
Jacob Elgrably is Chief Shalpharm of Rekah Pharmaceutical Industry
| Phone | 972 3 558 1233 |
| Web | https://www.rekah.co.il |
Rekah Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0208 % which means that it generated a profit of $0.0208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0222 %, meaning that it generated $0.0222 on every $100 dollars invested by stockholders. Rekah Pharmaceutical's management efficiency ratios could be used to measure how well Rekah Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nir Deri | PCB Tec | 54 | |
| Ari Shamiss | Kamada | N/A | |
| Jeff Serrano | PCB Tec | N/A | |
| Ron Alkalai | Unitronics | 53 | |
| Lilach Topilsky | Kamada | N/A | |
| Thomas Bardor | Ashot Ashkelon Industries | N/A | |
| Tali PedhazurZuri | PCB Tec | 53 | |
| Reuven Avni | PCB Tec | 52 | |
| Itzhak Hai | Unitronics | 55 | |
| Ivgeny Blokh | Unitronics | N/A | |
| Albert Betz | Unitronics | N/A | |
| Amit Moshe | Ashot Ashkelon Industries | 40 | |
| Tomer Dvash | PCB Tec | 43 | |
| Ariella Raban | Kamada | 47 | |
| Sasson Darvish | Bet Shemesh Engines | 60 | |
| Eran Nir | Kamada | 50 | |
| Hanni Neheman | Kamada | 53 | |
| Lilach Zinger | PCB Tec | 49 | |
| Efrat Shanan | Bet Shemesh Engines | 52 | |
| Boaz Karmy | Unitronics | 57 | |
| Yaela HagaiLevi | Unitronics | 51 | |
Management Performance
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 |
Rekah Pharmaceutical Leadership Team
Elected by the shareholders, the Rekah Pharmaceutical's board of directors comprises two types of representatives: Rekah Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rekah. The board's role is to monitor Rekah Pharmaceutical's management team and ensure that shareholders' interests are well served. Rekah Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rekah Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yuval Elgrabli, Deputy Devel | ||
| Yuval CPA, Chief Officer | ||
| Jacob Elgrably, Chief Shalpharm | ||
| Chaim Cohen, Chief Officer | ||
| Jack Azran, Chief Technologies | ||
| Yaakov Elgrabli, Chief Ltd | ||
| Georgette Elgrabli, Director Director | ||
| Meir Melumad, Director Operations | ||
| Mordechai Elgrabli, CEO Director |
Rekah Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rekah Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 316.92 M | |||
| Shares Outstanding | 11.41 M | |||
| Shares Owned By Insiders | 37.27 % | |||
| Shares Owned By Institutions | 42.66 % | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.63 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rekah Stock
Rekah Pharmaceutical financial ratios help investors to determine whether Rekah Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rekah with respect to the benefits of owning Rekah Pharmaceutical security.